Skip to main content
News

BioFactura Announces Entry into Non-Exclusive License Agreement with Momenta Pharmaceuticals

By September 27, 2016No Comments
BioFactura-Logo-Vector-PNG700

 

BioFactura-Logo-Vector-PNG700Next Proposal Deadline October 14, 2016

BioFactura, Inc., an emerging Maryland biopharmaceutical research and manufacturing company, announced today entry into a non-exclusive license agreement with Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, relating to one of the biosimilar product candidates that Momenta is developing.  As part of this non-exclusive license agreement, BioFactura is developing a cell line using its NS0-based StableFastTM Biomanufacturing Platform, a proprietary system to rapidly generate stable cell lines that have the potential to lower cost, produce follow-on biologics and are single-use technology compatible.  The companies are actively working together to further optimize productivity.  Momenta has the right to obtain an exclusive research and commercial license to StableFastTM for clinical development and commercial manufacture of the undisclosed biosimilar product candidate.

{iframe}http://www.biofactura.com/biofactura-announces-entry-into-non-exclusive-license-agreement-with-momenta-pharmaceuticals/{/iframe}
BioFactura, Inc., an emerging Maryland biopharmaceutical research and manufacturing company, announced today entry into a non-exclusive license agreement with Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, relating to one of the biosimilar product candidates that Momenta is developing.  As part of this non-exclusive license agreement, BioFactura is developing a cell line using its NS0-basedStableFastTM Biomanufacturing Platform, a proprietary system to rapidly generate stable cell lines that have the potential to lower cost, produce follow-on biologics and are single-use technology compatible.  The companies are actively working together to further optimize productivity.  Momenta has the right to obtain an exclusive research and commercial license to StableFastTM for clinical development and commercial manufacture of the undisclosed biosimilar product candidate.

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.